Drugs / recombinant fowlpox-prostate specific antigen vaccine
recombinant fowlpox-prostate specific antigen vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00020254 | Jun 2000 → Oct 2004 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00005039 | Jan 2000 → Mar 2007 | prostate adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-prostate specific antigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00020254 ↗ |
| Action | Deplete | “Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells” NCT00005039 ↗ |
| Modality | Vaccine | “recombinant fowlpox-PSA vaccine” NCT00005039 ↗ |
| Route | Intramuscular | “Given IM” NCT00005039 ↗ |